Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Apparent diffusion coefficient measurement by diffusion weighted magnetic resonance imaging is a useful tool in differentiating renal tumors

Authors: Jing-Hong Liu, Shi-Feng Tian, Ye Ju, Ye Li, An-Liang Chen, Li-Hua Chen, Ai-Lian Liu

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

To determine the clinical value of apparent diffusion coefficient (ADC) measurement by diffusion weighted magnetic resonance imaging (DW-MRI) in differentiating renal tumors.

Methods

Electronic databases were searched using combinations of keywords and free words relating to renal tumor, ADC and DW-MRI. Based on carefully selected inclusion and exclusion criteria, relevant case–control studies were identified and the related clinical data was acquired. Statistical analyses were performed using STATA 12.0 (Stata Corporation, College station, TX).

Results

Sixteen case–control studies were ultimately included in the present meta-analysis. These 16 high quality studies contained a combined total of 438 normal renal tissues and 832 renal tumor lesions (597 malignant and 235 benign). The results revealed that ADC values of malignant renal tumor tissues were markedly lower than normal renal tissues and benign renal tumor tissues. ADC values of benign renal tumor tissues were also significantly lower than normal renal tissue.

Conclusions

ADC measurement by DW-MRI provided clinically useful information on the internal structure of renal tumors and could be an important radiographic index for differentiation of malignant renal tumors from benign renal tumors.
Appendix
Available only for authorised users
Literature
1.
2.
Purdue MP, Moore LE, Merino MJ, Boffetta P, Colt JS, Schwartz KL, et al. An investigation of risk factors for renal cell carcinoma by histologic subtype in two case–control studies. Int J Cancer J Int du cancer. 2013;132(11):2640–7.CrossRef
3.
Gudmundsson J, Sulem P, Gudbjartsson DF, Masson G, Petursdottir V, Hardarson S, et al. A common variant at 8q24.21 is associated with renal cell cancer. Nat Commun. 2013;4:2776.CrossRefPubMed
4.
Lipworth L, Morgans AK, Edwards TL, Barocas DA, Chang SS, Herrell SD, et al. Renal cell cancer histologic subtype distribution differs by race and sex. BJU Int. 2014. Oct 13. doi:10.1111/bju.12950. [Epub ahead of print].
5.
Escudier B, Eisen T, Porta C, Patard JJ, Khoo V, Algaba F, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(7):vii65–71.PubMed
6.
Majid S, Saini S, Dar AA, Hirata H, Shahryari V, Tanaka Y, et al. MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res. 2011;71(7):2611–21.CrossRefPubMedPubMedCentral
7.
Olshan AF, Kuo TM, Meyer AM, Nielsen ME, Purdue MP, Rathmell WK. Racial difference in histologic subtype of renal cell carcinoma. Cancer Med. 2013;2(5):744–9.PubMedPubMedCentral
8.
Ng KL, Rajandram R, Morais C, Yap NY, Samaratunga H, Gobe GC, et al. Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem? J Clin Pathol. 2014;67(2):97–104.CrossRefPubMed
9.
Goyal A, Sharma R, Bhalla AS, Gamanagatti S, Seth A. Pseudotumours in chronic kidney disease: can diffusion-weighted MRI rule out malignancy. Eur J Radiol. 2013;82(11):1870–6.CrossRefPubMed
10.
Razek AA, Farouk A, Mousa A, Nabil N. Role of diffusion-weighted magnetic resonance imaging in characterization of renal tumors. J Comput Assist Tomogr. 2011;35(3):332–6.CrossRefPubMed
11.
12.
Ozarslan E, Koay CG, Shepherd TM, Komlosh ME, Irfanoglu MO, Pierpaoli C, et al. Mean apparent propagator (MAP) MRI: a novel diffusion imaging method for mapping tissue microstructure. Neuroimage. 2013;78:16–32.CrossRefPubMedPubMedCentral
13.
Niu X, Das SK, Bhetuwal A, Xiao Y, Sun F, Zeng L, et al. Value of diffusion-weighted imaging in distinguishing pancreatic carcinoma from mass-forming chronic pancreatitis: a meta-analysis. Chin Med J (Engl). 2014;127(19):3477–82.
14.
Tanaka H, Yoshida S, Fujii Y, Ishii C, Tanaka H, Koga F, et al. Diffusion-weighted magnetic resonance imaging in the differentiation of angiomyolipoma with minimal fat from clear cell renal cell carcinoma. Int J Urol. 2011;18(10):727–30.CrossRefPubMed
15.
Goyal A, Sharma R, Bhalla AS, Gamanagatti S, Seth A, Iyer VK, et al. Diffusion-weighted MRI in renal cell carcinoma: a surrogate marker for predicting nuclear grade and histological subtype. Acta Radiol. 2012;53(3):349–58.CrossRefPubMed
16.
Baltzer PA, Renz DM, Herrmann KH, Dietzel M, Krumbein I, Gajda M, et al. Diffusion-weighted imaging (DWI) in MR mammography (MRM): clinical comparison of echo planar imaging (EPI) and half-Fourier single-shot turbo spin echo (HASTE) diffusion techniques. Eur Radiol. 2009;19(7):1612–20.CrossRefPubMed
17.
Tsougos I, Svolos P, Kousi E, Fountas K, Theodorou K, Fezoulidis I, et al. Differentiation of glioblastoma multiforme from metastatic brain tumor using proton magnetic resonance spectroscopy, diffusion and perfusion metrics at 3 T. Cancer Imaging. 2012;12:423–36.CrossRefPubMedPubMedCentral
18.
Kido A, Fujimoto K, Okada T, Togashi K. Advanced MRI in malignant neoplasms of the uterus. J Magn Reson Imaging. 2013;37(2):249–64.CrossRefPubMed
19.
Lecouvet FE, Lhommel R, Pasoglou V, Larbi A, Jamar F, Tombal B. Novel imaging techniques reshape the landscape in high-risk prostate cancers. Curr Opin Urol. 2013;23(4):323–30.CrossRefPubMed
20.
Wang H, Cheng L, Zhang X, Wang D, Guo A, Gao Y, et al. Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 T. Radiology. 2010;257(1):135–43.CrossRefPubMed
21.
Sevcenco S, Heinz-Peer G, Ponhold L, Javor D, Kuehhas FE, Klingler HC, et al. Utility and limitations of 3-Tesla diffusion-weighted magnetic resonance imaging for differentiation of renal tumors. Eur J Radiol. 2014;83(6):909–13.CrossRefPubMed
22.
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–6.CrossRefPubMed
23.
Zintzaras E, Ioannidis JP. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.CrossRefPubMed
24.
Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28(2):123–37.CrossRefPubMed
25.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMed
26.
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61(10):991–6.CrossRefPubMed
27.
28.
Ferrenberg AM, Swendsen RH. New Monte Carlo technique for studying phase transitions. Phys Rev Lett. 1988;61(23):2635–8.CrossRefPubMed
29.
Zhang YL, Yu BL, Ren J, Qu K, Wang K, Qiang YQ, et al. EADC values in diagnosis of renal lesions by 3.0 T diffusion-weighted magnetic resonance imaging: compared with the ADC values. Appl Magn Reson. 2013;44(3):349–63.CrossRefPubMed
30.
Agnello F, Roy C, Bazille G, Galia M, Midiri M, Charles T, et al. Small solid renal masses: characterization by diffusion-weighted MRI at 3 T. Clin Radiol. 2013;68(6):e301–8.CrossRefPubMed
31.
Yu X, Lin M, Ouyang H, Zhou C, Zhang H. Application of ADC measurement in characterization of renal cell carcinomas with different pathological types and grades by 3.0T diffusion-weighted MRI. Eur J Radiol. 2012;81(11):3061–6.CrossRefPubMed
32.
Rheinheimer S, Stieltjes B, Schneider F, Simon D, Pahernik S, Kauczor HU, et al. Investigation of renal lesions by diffusion-weighted magnetic resonance imaging applying intravoxel incoherent motion-derived parameters–initial experience. Eur J Radiol. 2012;81(3):e310–6.CrossRefPubMed
33.
Inci E, Hocaoglu E, Aydin S, Cimilli T. Diffusion-weighted magnetic resonance imaging in evaluation of primary solid and cystic renal masses using the Bosniak classification. Eur J Radiol. 2012;81(5):815–20.CrossRefPubMed
34.
Zhang YL, Yu BL, Wang K, Quan GN, Sun XW, Qiang YQ, et al. Significance of diffusion-weighted magnetic resonance imaging in the diagnosis of common nephropathy. J Modern Urol. 2011;16(3):206–9.
35.
Zhang J, Ou Yang H, Chen Y, Dai JR, Zhou CW. MR imageing features of papillary renal cell carcinoma. J Med Imaging. 2011;21(5):718–22.
36.
Doganay S, Kocakoc E, Cicekci M, Aglamis S, Akpolat N, Orhan I. Ability and utility of diffusion-weighted MRI with different b values in the evaluation of benign and malignant renal lesions. Clin Radiol. 2011;66(5):420–5.CrossRefPubMed
37.
Kim S, Jain M, Harris AB, Lee VS, Babb JS, Sigmund EE, et al. T1 hyperintense renal lesions: characterization with diffusion-weighted MR imaging versus contrast-enhanced MR imaging. Radiology. 2009;251(3):796–807.CrossRefPubMed
38.
Kilickesmez O, Inci E, Atilla S, Tasdelen N, Yetimoglu B, Yencilek F, et al. Diffusion-weighted imaging of the renal and adrenal lesions. J Comput Assist Tomogr. 2009;33(6):828–33.CrossRefPubMed
39.
Manenti G, Di Roma M, Mancino S, Bartolucci DA, Palmieri G, Mastrangeli R, et al. Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T. Radiol Med. 2008;113(2):199–213.CrossRefPubMed
40.
Yoshikawa T, Kawamitsu H, Mitchell DG, Ohno Y, Ku Y, Seo Y, et al. ADC measurement of abdominal organs and lesions using parallel imaging technique. AJR Am J Roentgenol. 2006;187(6):1521–30.CrossRefPubMed
41.
Squillaci E, Manenti G, Cova M, Di Roma M, Miano R, Palmieri G, et al. Correlation of diffusion-weighted MR imaging with cellularity of renal tumours. Anticancer Res. 2004;24(6):4175–9.PubMed
42.
Freiman M, Voss SD, Mulkern RV, Perez-Rossello JM, Callahan MJ, Warfield SK. Reliable assessment of perfusivity and diffusivity from diffusion imaging of the body. Med Image Comput Comput Assist Interv. 2012;15(Pt 1):1–9.PubMedPubMedCentral
43.
Freiman M, Voss SD, Mulkern RV, Perez-Rossello JM, Callahan MJ, Warfield SK. In vivo assessment of optimal b-value range for perfusion-insensitive apparent diffusion coefficient imaging. Med Phys. 2012;39(8):4832–9.CrossRefPubMedPubMedCentral
44.
Sasaki M, Eida S, Sumi M, Nakamura T. Apparent diffusion coefficient mapping for sinonasal diseases: differentiation of benign and malignant lesions. AJNR Am J Neuroradiol. 2011;32(6):1100–6.CrossRefPubMed
45.
Taouli B, Thakur RK, Mannelli L, Babb JS, Kim S, Hecht EM, et al. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology. 2009;251(2):398–407.CrossRefPubMed
46.
Moriyama S, Yoshida S, Takeshita H, Kurata M, Okada Y, Saito K, et al. Case of inflammatory lesion in urinary bladder showing high signal intensity on diffusion-weighted MRI: correlation with histopathological finding. Nihon Hinyokika Gakkai zasshi Japanese J Urol. 2013;104(3):545–8.
47.
Lambregts DM, Maas M, Riedl RG, Bakers FC, Verwoerd JL, Kessels AG, et al. Value of ADC measurements for nodal staging after chemoradiation in locally advanced rectal cancer-a per lesion validation study. Eur Radiol. 2011;21(2):265–73.CrossRefPubMed
48.
Kobayashi S, Koga F, Yoshida S, Masuda H, Ishii C, Tanaka H, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. Eur Radiol. 2011;21(10):2178–86.CrossRefPubMed
49.
Paudyal B, Paudyal P, Tsushima Y, Oriuchi N, Amanuma M, Miyazaki M, et al. The role of the ADC value in the characterisation of renal carcinoma by diffusion-weighted MRI. Br J Radiol. 2010;83(988):336–43.CrossRefPubMedPubMedCentral
50.
Messiou C, Collins DJ, Morgan VA, Bianchini D, De Bono JS, De Souza NM. Use of apparent diffusion coefficient as a response biomarker in bone: effect of developing sclerosis on quantified values. Skeletal Radiol. 2014;43(2):205–8.CrossRefPubMed
51.
Koc Z, Erbay G. Optimal b value in diffusion-weighted imaging for differentiation of abdominal lesions. J Magn Reson Imaging. 2014;40(3):559–66.CrossRefPubMed
52.
Childs DD, Clingan MJ, Zagoria RJ, Sirintrapun J, Tangtiang K, Anderson A, et al. In-phase signal intensity loss in solid renal masses on dual-echo gradient-echo MRI: association with malignancy and pathologic classification. AJR Am J Roentgenol. 2014;203(4):W421–8.CrossRefPubMed
53.
Tang Y, Zhou Y, Du W, Liu N, Zhang C, Ouyang T, et al. Standard b-value versus low b-value diffusion-weighted MRI in renal cell carcinoma: a systematic review and meta-analysis. BMC Cancer. 2014;14:843.CrossRefPubMedPubMedCentral
Metadata
Title
Apparent diffusion coefficient measurement by diffusion weighted magnetic resonance imaging is a useful tool in differentiating renal tumors
Authors
Jing-Hong Liu
Shi-Feng Tian
Ye Ju
Ye Li
An-Liang Chen
Li-Hua Chen
Ai-Lian Liu
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1221-1

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Study protocol

Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study

Research article

ZFP36 stabilizes RIP1 via degradation of XIAP and cIAP2 thereby promoting ripoptosome assembly

Research article

Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker

Study protocol

eCROPS-CA: a systematic approach toward effective and sustainable cancer prevention in rural China

Research article

Diagnostic intervals before and after implementation of cancer patient pathways – a GP survey and registry based comparison of three cohorts of cancer patients

Case report

Enormous, rapidly growing breast mass
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits